WO2005007137A8 - Ambroxolhaltige tabletten - Google Patents

Ambroxolhaltige tabletten

Info

Publication number
WO2005007137A8
WO2005007137A8 PCT/EP2004/007849 EP2004007849W WO2005007137A8 WO 2005007137 A8 WO2005007137 A8 WO 2005007137A8 EP 2004007849 W EP2004007849 W EP 2004007849W WO 2005007137 A8 WO2005007137 A8 WO 2005007137A8
Authority
WO
WIPO (PCT)
Prior art keywords
tablets containing
ambroxol
containing ambroxol
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
PCT/EP2004/007849
Other languages
English (en)
French (fr)
Other versions
WO2005007137A3 (de
WO2005007137A2 (de
Inventor
Anja Kohlrausch
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Anja Kohlrausch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10360086A external-priority patent/DE10360086A1/de
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Anja Kohlrausch filed Critical Boehringer Ingelheim Int
Priority to CA002532485A priority Critical patent/CA2532485A1/en
Priority to EP04763241A priority patent/EP1648423A2/de
Publication of WO2005007137A2 publication Critical patent/WO2005007137A2/de
Publication of WO2005007137A3 publication Critical patent/WO2005007137A3/de
Publication of WO2005007137A8 publication Critical patent/WO2005007137A8/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft den Wirkstoff Ambroxol oder eines seiner pharmakologisch verträglichen Salze enthaltende Tabletten, wobei der Ambroxolgehalt pro Tablette in einem Bereich von 250 bis 1000 mg liegt.
PCT/EP2004/007849 2003-07-16 2004-07-15 Ambroxolhaltige tabletten WO2005007137A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002532485A CA2532485A1 (en) 2003-07-16 2004-07-15 Tablets containing ambroxol
EP04763241A EP1648423A2 (de) 2003-07-16 2004-07-15 Ambroxolhaltige tabletten

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10332458.5 2003-07-16
DE10332458 2003-07-16
DE10360086A DE10360086A1 (de) 2003-07-16 2003-12-20 Ambroxolhaltige Tabletten
DE10360086.8 2003-12-20

Publications (3)

Publication Number Publication Date
WO2005007137A2 WO2005007137A2 (de) 2005-01-27
WO2005007137A3 WO2005007137A3 (de) 2005-04-28
WO2005007137A8 true WO2005007137A8 (de) 2006-09-21

Family

ID=34081653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/007849 WO2005007137A2 (de) 2003-07-16 2004-07-15 Ambroxolhaltige tabletten

Country Status (4)

Country Link
US (1) US20050027012A1 (de)
EP (1) EP1648423A2 (de)
CA (1) CA2532485A1 (de)
WO (1) WO2005007137A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1976488A4 (de) * 2006-01-12 2010-02-10 Wockhardt Ltd Zusammensetzungen aus alfuzosin mit verzögerter freisetzung
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
EP2566469B1 (de) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Kombinationstherapie
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
TW201521794A (zh) * 2013-11-12 2015-06-16 Daiichi Sankyo Co Ltd 錠劑
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN108113971B (zh) * 2016-11-28 2021-12-28 北京科信必成医药科技发展有限公司 一种盐酸氨溴索掩味制剂及其制备方法
CN112773769B (zh) * 2019-11-07 2022-11-15 烟台东诚药业集团股份有限公司 一种盐酸氨溴索分散片及其制法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593579B1 (de) * 1966-05-10 1972-02-03 Thomae Gmbh Dr K Hydroxy-cyclohexylamine,deren physiologisch vertraeglichen Saeureadditionssalze und Verfahren zu ihrer Herstellung
EP0138020B1 (de) * 1983-09-17 1992-06-03 Dr. Karl Thomae GmbH Antiadhäsive Prophylactica und Arzneimittel enthaltend ein sekretolytisch wirksames Benzylaminderivat
DE10203104A1 (de) * 2002-01-25 2003-08-07 Boehringer Ingelheim Pharma Ambroxol für die Behandlung chronischer Schmerzen

Also Published As

Publication number Publication date
WO2005007137A3 (de) 2005-04-28
CA2532485A1 (en) 2005-01-27
WO2005007137A2 (de) 2005-01-27
EP1648423A2 (de) 2006-04-26
US20050027012A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2005007137A8 (de) Ambroxolhaltige tabletten
EP0960621A3 (de) Pharmazeutische Zusammensetzungen enthaltend sildenafil
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
MXPA03007712A (es) Sales farmaceuticas.
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2004058837A3 (de) Ampholytisches copolymer und dessen verwendung
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
AU2003286994A1 (en) Modified release pharmaceutical composition
EP1419785A4 (de) Arzneimittel mit einem chymase-hemmer und einem ace-hemmer als wirkstoffe
EP1550448A4 (de) Histamin-freisetzungshemmer
AU2003223989A1 (en) System for orally administering active substances, vitamins and/or foodstuffs
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
CA2379314A1 (en) Tablet for sucking, containing ambroxol
WO2005051350A3 (en) Water dispersible tablet
AR038206A1 (es) Composicion farmaceutica dispersable oralmente de ivabradina
WO2007016350A3 (en) Modified release tablet formulations with enhanced mechanical properties
WO2005065047A3 (en) Stable oral composition containing desloratadine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004763241

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2532485

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006519877

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004763241

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004763241

Country of ref document: EP